Patient description: The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Digestive Cancer Patient age ≥ 18 years 2. Histological or cytological diagnosis of peritoneal carcinoma of colorectal, gastric or gray primitive 3. Having previously received at least 3 months of systemic chemotherapy for metastatic disease (type of chemotherapy left to the discretion of each investigator). Patients who received chemotherapy with bevacizumab (Avastin®) more than 2 months ago may be included. 4. Irritable or extensive peritoneal carcinosis: Extended peritoneal carcinoma of gastric adenocarcinoma (PCI score> 5) Extended peritoneal carcinoma of adenocarcinoma (PCI score> 13) Extended peritoneal carcinoma of colorectal adenocarcinoma (PCI score> 15) 5. ECOG performance index < or = 2 (see Annex 8) 6. Life expectancy> 3 months 7. Peripheral neuropathy grade ≤ 1 8. Hematological function: Hemoglobin ≥ 9 g / dL, leukocytes ≥ 4000 / mm3, PNN ≥ 1500 / mm3, platelets ≥ 100 000 / mm3 9. creatinine clearance> 50 mL / min (cockcroft and Gault formula) 10. Hepatic function: Total bilirubin ≤ 1.5 x ULN, ASAT and ALAT ≤ 3 x ULN, Alkaline phosphatases ≤ 3 x ULN 11. Patient without deficiency or with partial deficiency in Dihydropyrimidine dehydrogenase (i.e. DPD) 12. Effective contraception for women of childbearing age 13. Informing the patient and obtaining free, informed and written consent signed by the patient and his / her investigator. 14. Affiliated subject or beneficiary of the social security scheme  Patients who received bevacizumab (Avastin®) less than 2 months ago can not be included 2. Extra-peritoneal metastases, except for less than 3 pulmonary nodules (each size <5mm) 3. Known hypersensitivity to Oxaliplatin 4. Complete deficiency of Dihydropyrimidine dehydrogenase (i.e. DPD) 5. Grade 1> grade 1 peripheral neuropathy due to or not with Oxaliplatin previously used 6. Active active or other serious underlying disease that may prevent the patient from receiving treatment 7. Intracranial or intraocular hypertension (ongoing at the time of inclusion) 8. Severe or Severe Heart Failure (ongoing at the time of inclusion) 9. Complete intestinal obstruction (ongoing at the time of inclusion) 10. Other concurrent cancer or history of cancer other than in situ cancer of treated cervix or basal cell carcinoma or squamous cell carcinoma 11. Pregnant or nursing women 12. Persons deprived of their liberty or under guardianship or unable to give their consent 13. Inability to submit to medical follow-up of the trial for geographical, social or psychological reasons 14. Long-term corticosteroids (duration> 3 months), except for weaning for at least 3 months